ストックスクリーナーアプリを入手
6.71
1.05%
0.07
アフターアワーズ：
6.73
0.02
+0.30%
前日終値:
$6.64
開ける：
$6.67
24時間の取引高:
108.72K
Relative Volume:
1.04
時価総額：
$170.82M
収益：
-
当期純損益:
$-22.38M
株価収益率:
-4.7589
EPS:
-1.41
ネットキャッシュフロー:
$-15.54M
1週間 パフォーマンス:
+8.23%
1か月 パフォーマンス:
+11.46%
6か月 パフォーマンス:
-32.63%
1年 パフォーマンス:
-10.17%
1日の値動き範囲:
$6.61
$6.80
1週間の範囲:
$6.1201
$7.00
52週間の値動き範囲:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
名前
Nuvectis Pharma Inc
セクター
電話
360-837-7232
住所
1 BRIDGE PLAZA, SUITE 275, FORT LEE
NVCT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.71 | 169.03M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | 開始されました | Maxim Group | Buy |
| 2025-03-17 | 開始されました | Laidlaw | Buy |
| 2022-07-13 | 開始されました | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc (NVCT) 最新ニュース
Predicting Nuvectis Pharma Inc. trend using moving averagesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
What makes Nuvectis Pharma Inc. stock attractive to growth funds2025 Market Sentiment & AI Forecast Swing Trade Picks - newser.com
Plaza Wires Limited Company Forecast Revenue EPS and Valuation OutlookEarnings Miss Alerts & Get Peace of Mind with Portfolio Health Checks - earlytimes.in
Nuvectis Pharma Shares: Poised for Significant Growth? - AD HOC NEWS
How strong is Nuvectis Pharma Inc. stock revenue growthBull Run & Weekly Top Gainers Trade List - newser.com
Nuvectis Pharma : Initial Statement of Beneficial Ownership (Form 3) - MarketScreener
What data driven models say about Nuvectis Pharma Inc.’s futureMarket Volume Summary & Smart Investment Allocation Insights - newser.com
Does Nuvectis Pharma Inc. qualify in momentum factor screening2025 Price Momentum & Advanced Technical Signal Analysis - newser.com
How Nuvectis Pharma Inc. stock performs in rate cut cyclesTrade Risk Summary & Long-Term Safe Investment Plans - newser.com
Using RSI to spot recovery in Nuvectis Pharma Inc.Treasury Yields & Long-Term Growth Plans - newser.com
Insider Buying: Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Acquires 46,900 Shares of Stock - MarketBeat
Insider Buying: Nuvectis Pharma (NASDAQ:NVCT) Major Shareholder Purchases 72,836 Shares of Stock - MarketBeat
A US$22m Market Cap Boost Pleasing ToNuvectis Pharma Insiders - simplywall.st
What's Driving Renewed Interest In Nuvectis Pharma's Oncology Strategy? - RTTNews
Major Investment Alert: Insider Buys Big in Nuvectis Pharma! - TipRanks
Why Nuvectis Pharma Inc. stock remains undervaluedProfit Target & Daily Oversold Stock Bounce Ideas - newser.com
Insider Stock Purchases: October 29, 2025 - Quiver Quantitative
Nuvectis Pharma Stock (NVCT) Opinions on NXP900 Trial Results - Quiver Quantitative
Nuvectis Pharma (NVCT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing - MarketScreener
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
Can Nuvectis Pharma Inc. stock hit analyst price targetsMarket Volume Summary & Daily Technical Forecast Reports - fcp.pa.gov.br
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target By Investing.com - Investing.com South Africa
Can Nuvectis Pharma Inc. stock reach $100 price targetJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - fcp.pa.gov.br
Will Nuvectis Pharma Inc. stock beat EPS estimatesWatch List & Consistent Growth Equity Picks - newser.com
Nuvectis Pharma Inc. stock trendline breakdownJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - newser.com
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Nuvectis (NASDAQ: NVCT): NXP900 PD ≥150 mg/day; Phase 1b underway; no CYP450 induction - Stock Titan
Nuvectis Pharma Inc (NVCT) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):